多囊卵巢综合征市场研究报告 - 预测到2027年

Polycystic Ovarian Syndrome Market Research Report, By Diagnosis (Pelvic Examination, Ultrasound, Blood Tests), Treatment (Oral Contraceptives, Antiandrogens), End-User (Hospitals & Clinics, Ambulatory Surgical Centers) – Global Forecast Till 2027

ID: MRFR/Pharma/4834-HCR | | Region: Global | 100 pages

Polycystic Ovarian Syndrome Market Scenario


Polycystic Ovary Syndrome (PCOS) is a medical condition where the women of reproductive age suffer from hormonal disorders. This is due to an increase in levels of male hormones in the body which leads to an irregular menstrual cycle. Women experience symptoms such as irregular menstrual cycle, increase in facial hair growth, acne, thinning hair or hair loss on the scalp, weight gain, darkening of skin and others. Polycystic Ovary Syndrome (PCOS) is caused due to high levels of androgens, excess insulin, low-grade inflammation, cysts in the ovaries, and genetic disorders.


The polycystic ovarian syndrome market is expected to witness tremendous growth owing to the rising prevalence of polycystic ovarian syndrome. According to the Centers for Disease Control and Prevention, approximately 5 million women of reproductive age suffer from the polycystic ovarian syndrome.


Other key factors such as the growing obesity among women, rising prevalence of diabetes, increasing hormonal disorders in women, change in sedentary lifestyle, socioeconomic factors, growing consumption of unhealthy diet, and others are contributing towards the growth of the market. Diabetes is another risk factor that leads to the development of the polycystic ovarian syndrome. Such factors contribute to polycystic ovarian syndrome among women.


然而,副作用等因素相关ith drugs such as weight gain, cardiovascular risks, increase insulin resistance, abnormal glucose tolerance, and thromboembolic events are expected to restrict the market growth during the forecast period.


Segmentation


多囊卵巢综合征市场是在诊断，治疗和最终用户的基础上进行分割的。通过诊断，多囊卵巢综合征市场分为骨盆检查，经阴道超声和验血。血液试验进一步分段为激素水平，葡萄糖耐量和胆固醇和甘油三酯水平。在治疗的基础上，市场被分段为口服避孕药，抗抗原，胰岛素敏化剂，抗抑郁药，抗肥胖和手术。手术类别包括卵巢楔切除术和腹腔镜卵巢钻探。在最终用户的基础上，该市场被分段为医院和诊所，外科手术中心，诊断中心，妇科中心，女权主义保健中心等。


的基础上,多囊卵巢syndrome market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and South America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia-Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.


Key players


Some of the key players in the polycystic ovarian syndrome market are Bayer AG, AstraZeneca plc, Abbott, Biocinese, Catalysis, S.L., Crinetics Pharmaceuticals, Inc., Sanofi, Eugonia, EffRx, Inc., Ferring Pharmaceuticals, Inc., Merck KGaA, Bristol-Myer Squibb Company, Neurocrine Biosciences, Inc., Reliance Life Sciences Pvt. Ltd. Pfizer, Inc., Novartis AG, and Shire Plc.


区域市场摘要


多囊卵巢综合征市场份额（％），按地区，2017年


Polycystic Ovarian Syndrome Market Share


来源：疾病控制和预防中心，妇女卫生办公室，助理卫生局局长，美国卫生和人类服务部。


The polycystic ovarian syndrome market is dominated by North America owing to the rising obesity. According to the Institute for Health Metrics and Evaluation (IHME), 60% of women were obese or overweight in 2013. Other factors such as increasing healthcare expenditure, increasing technological advancements, and adoption of minimally invasive surgeries drive the market growth in this region.


据估计,欧洲第二大in the polycystic ovarian syndrome market owing to the increasing prevalence of diabetes, obesity, and increasing research activities in the health industry in this region. According to the German Federal Ministry of Health in 2014 and 2015, 7.0% of women of age 18 and more suffered from diabetes in Germany. Thus, the increasing prevalence of diabetes in this region influences the growth of this market in this region.


亚太was projected to be the fastest growing region for the polycystic ovarian syndrome market in 2017. The market is expected to witness growth owing to the rising prevalence of diabetes in women, changing lifestyle, and growing obesity within the female population. This provides favorable backgrounds for the market to grow.


The Middle East and Africa holds the least share in the polycystic ovarian syndrome market due to the presence of stringent government policies and poor economies. However, the market is expected to witness growth due to the rising healthcare expenditure, growing private sector in the healthcare domain, and insurance coverage in the Middle East.


Market Segmentation and Key Market Players


Polycystic Ovarian Syndrome Market, by Diagnosis



  • 骨盆检查

  • Transvaginal超声波

  • Blood tests


    • 激素水平

    • Glucose tolerance

    • Cholesterol and triglyceride levels



Polycystic Ovarian Syndrome Market, by Treatment



  • Oral Contraceptives

  • Antiandrogens

  • Insulin Sensitizing Agent

  • Antidepressant

  • 反肥胖

  • 手术


    • Ovarian Wedge Resection

    • Laparoscopic Ovarian Drilling



Polycystic Ovarian Syndrome Market, by End-User



  • 医院和诊所

  • 外科手术中心

  • 诊断中心

  • Gynecology Centers

  • 女权主义保健中心


多囊卵巢综合征市场，按地区



  • Americas

  • Europe

  • 亚太

  • Middle East & Africa


Intended Audience



  • 药物companies

  • Biotechnological institutes

  • Government and private laboratories

  • 研发（研发）公司

  • Medical research laboratories

  • Market research and consulting service providers



Report Scope:
Report Attribute/Metric 细节
Market Size 202.7: Significant Value
CANG Substantial CAGR
Base Year 2019年
预测期 202.0-2027
Historical Data 2018年
预测单位 Value (USD Million)
Report Coverage 收入预测，竞争景观，增长因素和趋势
Segments Covered By Diagnosis, Treatment, End-User
覆盖着地理位置 North America, Europe, Asia-Pacific, and Rest of the World (RoW)
Key Vendors Bayer AG, AstraZeneca plc, Abbott, Biocinese, Catalysis, S.L., Crinetics Pharmaceuticals, Inc., Sanofi, Eugonia, EffRx, Inc., Ferring Pharmaceuticals, Inc., Merck KGaA, Bristol-Myer Squibb Company, Neurocrine Biosciences, Inc., Reliance Life Sciences Pvt. Ltd. Pfizer, Inc., Novartis AG, and Shire Plc
Key Market Opportunities

  • Increasing healthcare expenditure
  • Increasing technological advancements

    		•
    Key Market Drivers

  • Increasing hormonal disorders in women
  • Adoption of minimally invasive surgeries
  • Rising prevalence of diabetes

    		•


    与分析师交谈 Ask for Customization

    Frequently Asked Questions (FAQ) :

    North America is expected to lead the Polycystic Ovarian Syndrome Market.

    Increasing prevalence of diabetes and rising hormonal disorders among women is adding market growth.

    Certain side effects may limit market growth.

    多囊卵巢综合征市场的不同端使用产业包括女权主义卫生中心，妇科中心，医院和诊所等。

    Different strategies used by industry players to create a dominance in the Polycystic Ovarian Syndrome Market include mergers, collaborations, strategic alliances, and product launches.

    表中的内容

    CHAPTER 1. REPORT PROLOGUE

    CHAPTER 2. MARKET INTRODUCTION

    2.1定义

    2.2 SCOPE OF THE STUDY

    2.2.1研究OBJECTIVE

    2.2.2 ASSUMPTIONS

    2.2.3限制

    CHAPTER 3. RESEARCH METHODOLOGY

    3.1 INTRODUCTION

    3.2主要研究

    3.3 SECONDARY RESEARCH

    3.4 MARKET SIZE ESTIMATION

    第4章市场动态

    4.1 DRIVERS

    4.2束缚

    4.3 OPPORTUNITIES

    4.4 CHALLENGES

    4.5宏观经济指标

    4.6技术趋势与评估

    第5章市场因素分析

    5.1搬运工的五部队分析

    5.1.1 BARGAINING POWER OF SUPPLIERS

    5.1.2 BARGAINING POWER OF BUYERS

    5.1.3新进入者的威胁

    5.1.4替代威胁

    5.1.5竞争的强度

    5.2 VALUE CHAIN ANALYSIS

    5.3 INVESTMENT FEASIBILITY ANALYSIS

    5.4定价分析

    第6章全球性多囊卵巢综合征市场，诊断

    6.1 INTRODUCTION

    6.2 PELVIC EXAMINATION

    6.3 TRANSVAGINAL ULTRASOUND

    6.4 BLOOD TESTS

    6.4.1 HORMONE LEVELS

    6.4.2 GLUCOSE TOLERANCE

    6.4.3胆固醇和甘油三酯水平

    7. GLOBAL POLYCYSTIC OVARIAN SYNDROME MARKET, BY TREATMENT

    7.1 INTRODUCTION

    7.2 ORAL CONTRACEPTIVES

    7.3 ANTIANDROGENS

    7.4 INSULIN SENSITIZING AGENT

    7.5 ANTIDEPRESSANT

    7.6抗肥胖

    7.7 SURGERY

    7.7.1卵巢楔切除术

    7.7.2腹腔镜卵巢钻探

    第8章全球多囊卵巢综合征市场，最终用户

    8.1 INTRODUCTION

    8.2医院和诊所

    8.3 AMBULATORY SURGICAL CENTERS

    8.4 DIAGNOSTIC CENTERS

    8.5妇科中心

    8.6 FEMINIST HEALTH CENTERS

    CHAPTER 9. GLOBAL POLYCYSTIC OVARIAN SYNDROME MARKET, BY REGION

    9.1 INTRODUCTION

    9.2 AMERICA

    9.2.1北美洲

    9.2.1.1美国

    9.2.1.2 CANADA

    9.2.2 SOUTH AMERICA

    9.3 EUROPE

    9.3.1 WESTERN EUROPE

    9.3.1.1德国

    9.3.1.2 FRANCE

    9.3.1.3 ITALY

    9.3.1.4 SPAIN

    9.3.1.5 UK

    9.3.1.6西欧其他地区

    9.3.2 EASTERN EUROPE

    9.4亚太地区

    9.4.1日本

    9.4.2中国

    9.4.3 INDIA

    9.4.4 AUSTRALIA

    9.4.5 REPUBLIC OF KOREA

    9.4.6亚太地区其他地区

    9.5 MIDDLE EAST & AFRICA

    9.5.1 UNITED ARAB EMIRATES

    9.5.2 SAUDI ARABIA

    9.5.3 OMAN

    9.5.4科威特

    9.5.5卡塔尔

    9.5.6 REST OF THE MIDDLE EAST & AFRICA

    CHAPTER 10. COMPANY LANDSCAPE

    10.1介绍

    10.2 MARKET SHARE ANALYSIS

    10.3关键发展与策略

    10.3.1重点发展

    第11章公司档案

    11.1拜耳AG

    11.1.1 COMPANY OVERVIEW

    11.1.2键入概述

    11.1.3财务状况

    11.2.4 KEY DEVELOPMENTS

    11.1.5 SWOT分析

    11.2 ASTRAZENECA PLC

    11.2.1 COMPANY OVERVIEW

    11.2.2键入概述

    11.2.3财务概述

    11.2.4 KEY DEVELOPMENTS

    11.2.5 SWOT分析

    11.3 Abbott.

    11.3.1 COMPANY OVERVIEW

    11.3.2类型概述

    11.3.3 FINANCIAL OVERVIEW

    11.3.4关键开发

    11.3.5 SWOT分析

    11.4 Biocinese.

    11.4.1公司概述

    11.4.2 TYPE/BUSINESS SEGMENT OVERVIEW

    11.4.3财务概述

    11.4.4关键发展

    11.4.5 SWOT ANALYSIS

    11.5催化作用

    11.5.1公司概述

    11.5.2 TYPE OVERVIEW

    11.5.3 FINANCIAL OVERVIEW

    11.5.4关键发展

    11.5.5 SWOT分析

    11.6克罗米特药物，INC

    11.6.1 COMPANY OVERVIEW

    11.6.2 TYPE OVERVIEW

    11.6.3财务概述

    11.6.4 KEY DEVELOPMENTS

    11.6.5 SWOT ANALYSIS

    11.7 SANOFI.

    11.7.1 OVERVIEW

    11.7.2键入概述

    11.7.3 FINANCIALS

    11.7.4 KEY DEVELOPMENTS

    11.7.5 SWOT分析

    11.8 EUGONIA

    11.8.1概述

    11.8.2类型概述

    11.8.3财务人员

    11.8.4 KEY DEVELOPMENTS

    11.8.5 SWOT分析

    11.9 Effrx，Inc。

    11.9.1概述

    11.9.2键入概述

    11.9.3 FINANCIALS

    11.9.4重点发展

    11.9.5 SWOT ANALYSIS

    11.10 Ferring Pharmaceuticals，Inc

    11.10.1概述

    11.10.2类型概述

    11.10.3财务

    11.10.4 KEY DEVELOPMENTS

    11.10.5 SWOT ANALYSIS

    11.11默克kgaa.

    11.11.1 OVERVIEW

    11.11.2类型概述

    11.11.3 FINANCIALS

    11.11.4关键发展

    11.11.5 SWOT ANALYSIS

    11.12 BRISTOL-MYER SQUIBB COMPANY

    11.12.1 OVERVIEW

    11.12.2 TYPE OVERVIEW

    11.12.3财务

    11.12.4 KEY DEVELOPMENTS

    11.12.5 SWOT分析

    11.13 NEUROCRINE BIOSCIENCES

    11.13.1概述

    11.13.2 TYPE OVERVIEW

    11.13.3 FINANCIALS

    11.13.4 KEY DEVELOPMENTS

    11.13.5 SWOT ANALYSIS

    11.14 Reliance Life Sciences PVT。有限公司

    11.14.1 OVERVIEW

    11.14.2键入概述

    11.14.3财务

    11.14.4 KEY DEVELOPMENTS

    11.14.5 SWOT分析

    11.15 PFIZER, INC

    11.14.1 OVERVIEW

    11.14.2键入概述

    11.14.3财务

    11.14.4 KEY DEVELOPMENTS

    11.14.5 SWOT分析

    11.15其他人

    第12章附录

    表格列表

    TABLE 1 POLYCYSTIC OVARIAN SYNDROME MARKET INDUSTRY SYNOPSIS, 2020–2027

    表2全球多囊卵巢综合征市场估算和预测，2020-2027，（百万美元）

    表3全球多囊卵巢综合征市场，按地区，2020-2027，（百万美元）

    TABLE 4 GLOBAL POLYCYSTIC OVARIAN SYNDROME MARKET, BY DIAGNOSIS, 2020–2027, (USD MILLION)

    TABLE 5 GLOBAL POLYCYSTIC OVARIAN SYNDROME MARKET, BY TREATMENT, 2020–2027, (USD MILLION)

    表6全球多囊卵巢综合征市场，由最终用户，2020-2027，（百万美元）

    表7北美多囊卵巢综合征市场，诊断，2020-2027，（百万美元）

    表8北美多囊卵巢综合征市场，由治疗，2020-2027，（百万）

    TABLE 9 NORTH AMERICA POLYCYSTIC OVARIAN SYNDROME MARKET, BY END-USER, 2020–2027, (USD MILLION)

    表10美国多囊卵巢综合征市场，诊断，2020-2027，（百万美元）

    TABLE 11 US POLYCYSTIC OVARIAN SYNDROME MARKET, BY TREATMENT, 2020–2027, (USD MILLION)

    TABLE 12 US POLYCYSTIC OVARIAN SYNDROME MARKET, BY END-USER, 2020–2027, (USD MILLION)

    表13加拿大多囊卵巢综合征市场，诊断，2020-2027，（百万美元）

    TABLE 14 CANADA POLYCYSTIC OVARIAN SYNDROME MARKET, BY TREATMENT, 2020–2027, (USD MILLION)

    TABLE 15 CANADA POLYCYSTIC OVARIAN SYNDROME MARKET, BY END-USER, 2020–2027, (USD MILLION)

    表16南美多囊卵巢综合征市场，诊断，2020-2027，（百万美元）

    TABLE 17 SOUTH AMERICA POLYCYSTIC OVARIAN SYNDROME MARKET, BY TREATMENT, 2020–2027, (USD MILLION)

    表18南美洲多囊卵巢综合征市场，由最终用户，2020-2027，（百万美元）

    表19欧洲多囊卵巢综合征市场，诊断，2020-2027，（百万美元）

    TABLE 20 EUROPE POLYCYSTIC OVARIAN SYNDROME MARKET, BY TREATMENT, 2020–2027, (USD MILLION)

    TABLE 21 EUROPE POLYCYSTIC OVARIAN SYNDROME MARKET, BY END-USER, 2020–2027, (USD MILLION)

    表22西欧多囊卵巢综合征市场，诊断，2020-2027，（百万美元）

    TABLE 23 WESTERN EUROPE POLYCYSTIC OVARIAN SYNDROME MARKET, BY TREATMENT, 2020–2027, (USD MILLION)

    表24西欧多囊卵巢综合征市场，由最终用户，2020-2027，（百万美元）

    表25东欧多囊卵巢综合征市场，诊断，2020-2027，（百万美元）

    表26东欧多囊卵巢综合征市场，由治疗，2020-2027，（百万美元）

    TABLE 27 EASTERN EUROPE POLYCYSTIC OVARIAN SYNDROME MARKET, BY END-USER, 2020–2027, (USD MILLION)

    TABLE 28 ASIA-PACIFIC POLYCYSTIC OVARIAN SYNDROME MARKET, BY DIAGNOSIS, 2020–2027, (USD MILLION)

    TABLE 29 ASIA-PACIFIC POLYCYSTIC OVARIAN SYNDROME MARKET, BY TREATMENT, 2020–2027, (USD MILLION)

    表30亚太地区多囊卵巢综合征市场，由最终用户，2020-2027，（百万美元）

    表31中东和非洲多囊卵巢综合征市场，诊断，2020-2027，（百万美元）

    表32中东和非洲多囊卵巢综合征市场，由治疗，2020-2027，（百万美元）

    表33中东和非洲多囊卵巢综合征市场，由最终用户，2020-2027，（百万美元）

    LIST OF FIGURES

    FIGURE 1 RESEARCH PROCESS

    图2全球多囊卵巢综合征市场的分割

    FIGURE 3 MARKET DYNAMICS FOR GLOBAL POLYCYSTIC OVARIAN SYNDROME MARKET

    FIGURE 4 GLOBAL POLYCYSTIC OVARIAN SYNDROME MARKET SHARE, BY DIAGNOSIS 2020

    FIGURE 5 GLOBAL POLYCYSTIC OVARIAN SYNDROME MARKET SHARE, BY TREATMENT 2020

    FIGURE 6 GLOBAL POLYCYSTIC OVARIAN SYNDROME MARKET SHARE, BY END-USER, 2020

    FIGURE 7 GLOBAL POLYCYSTIC OVARIAN SYNDROME MARKET SHARE, BY REGION, 2020

    图8北美多囊卵巢综合征市场份额，由国家，2020年

    FIGURE 9 EUROPE POLYCYSTIC OVARIAN SYNDROME MARKET SHARE, BY COUNTRY, 2020

    图10亚太地区多囊卵巢综合征市场份额，由国家，2020年

    FIGURE 11 MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME MARKET SHARE, BY COUNTRY, 2020

    FIGURE 12 GLOBAL POLYCYSTIC OVARIAN SYNDROME MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

    FIGURE 13 BAYER AG: KEY FINANCIALS

    FIGURE 14 BAYER AG: SEGMENTAL REVENUE

    FIGURE 15 BAYER AG: GEOGRAPHICAL REVENUE

    FIGURE 16 ASTRAZENECA PLC: KEY FINANCIALS

    图17 Astazeneca PLC：分段收入

    FIGURE 18 ASTRAZENECA PLC: GEOGRAPHICAL REVENUE

    FIGURE 19 ABBOTT: KEY FINANCIALS

    图20 Abbott：分段收入

    FIGURE 21 ABBOTT: GEOGRAPHICAL REVENUE

    FIGURE 22 BIOCINESE: KEY FINANCIALS

    FIGURE 23 BIOCINESE: SEGMENTAL REVENUE

    图24生物皮肤：地理收入

    FIGURE 25 CRINETICS PHARMACEUTICALS, INC: KEY FINANCIALS

    图26克罗米特医药，公司：分段收入

    图27克罗米特医药，公司：地理收入

    图28催化：主要财务

    图29催化：分段收入

    FIGURE 30 CATALYSIS: GEOGRAPHICAL REVENUE

    FIGURE 31 SANOFI: KEY FINANCIALS

    FIGURE 32 SANOFI: SEGMENTAL REVENUE

    图33 Sanofi：地理收入

    图34尤尼尼亚：主要财务

    FIGURE 35 EUGONIA: SEGMENTAL REVENUE

    图36尤尼尼亚：地理收入

    图37 Effrx，Inc.:关键财务

    FIGURE 38 EFFRX, INC.: SEGMENTAL REVENUE

    图39 Effrx，Inc.:地理收入

    图40 Ferring Pharmaceuticals，Inc：主要财务

    FIGURE 41 FERRING PHARMACEUTICALS, INC: SEGMENTAL REVENUE

    图42 Ferring Pharmaceuticals，Inc：地理收入

    图46 Bristol-Myer Squibb公司：主要财务

    FIGURE 47 BRISTOL-MYER SQUIBB COMPANY: SEGMENTAL REVENUE

    图48 Bristol-Myer Squibb公司：地理收入

    FIGURE 49 NEUROCRINE BIOSCIENCES: KEY FINANCIALS

    FIGURE 50 NEUROCRINE BIOSCIENCES: SEGMENTAL REVENUE

    FIGURE 51 NEUROCRINE BIOSCIENCES: GEOGRAPHICAL REVENUE

    FIGURE 52 C.R. BARD: KEY FINANCIALS

    FIGURE 53 C.R. BARD: SEGMENTAL REVENUE

    图54 C.R. Bard：地理收入

    FIGURE 55 RELIANCE LIFE SCIENCES PVT. LTD: KEY FINANCIALS

    FIGURE 56 RELIANCE LIFE SCIENCES PVT. LTD: SEGMENTAL REVENUE

    图57 Reliance Life Sciences PVT。LTD：地理收入

    图58 PFizer，Inc：主要财务

    FIGURE 59 PFIZER, INC: SEGMENTAL REVENUE

    图60 PFizer，Inc：地理收入

    Baidu